Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. 10x Genomics Inc shares valued at $225,852 were sold by Taich Adam on Nov 24 ’25. At $19.00 per share, Taich Adam sold 11,888 shares. The insider’s holdings dropped to 297,385 shares worth approximately $5.74 million following the completion of this transaction.
Also, Hindson Benjamin J. sold 8,283 shares, netting a total of over 157,363 in proceeds. Following the sale of shares at $19.00 each, the insider now holds 432,605 shares.
Before that, Saxonov Serge had sold 13,261 shares from its account. In a trade valued at $251,936, the Chief Executive Officer traded 10x Genomics Inc shares for $19.00 each. Upon closing the transaction, the insider’s holdings decreased to 13,261 shares, worth approximately $19.71 million.
As published in a research note from Citigroup on December 11, 2025, 10x Genomics Inc [TXG] has been rated down from a Buy to a Neutral. Analysts at Morgan Stanley downgraded the stock from ‘”an Overweight”‘ to ‘”an Equal-weight”‘ outlook in a report released in early December. As of September 11, 2025, Piper Sandler has initiated its “Neutral” rating for TXG. Earlier on February 13, 2025, Leerink Partners downgraded its rating. Their new recommendation was “a Market perform” for TXG stock which previously was a “an Outperform”.
Analyzing TXG Stock Performance
On last trading session, 10x Genomics Inc [NASDAQ: TXG] plunged -3.50% to $19.29. The stock’s lowest price that day was $19.04, but it reached a high of $19.96 in the same session. During the last five days, there has been a surge of approximately 18.27%. Over the course of the year, 10x Genomics Inc shares have jumped approximately 21.17%. Shares of the company reached a 52-week high of $20.30 on 01/07/26 and a 52-week low of $16.23 on 01/02/26.
Support And Resistance Levels for 10x Genomics Inc (TXG)
According to the 24-hour chart, there is a support level at 18.86, which, if violated, would cause prices to drop to 18.43. In the upper region, resistance lies at 19.90. The next price resistance is at 20.52. RSI (Relative Strength Index) is 65.42 on the 14-day chart, showing neutral technical sentiment.
Is 10x Genomics Inc subject to short interest?
Stocks of 10x Genomics Inc saw a sharp steep in short interest on 2025-12-15 dropping by 80928.0 shares to 15.42 million. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 15.5 million shares. A decline of -0.52% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.8 of the overall float, the days-to-cover ratio (short ratio) decline to 5.8.
Which companies own the most shares of 10x Genomics Inc (TXG)?
In terms of 10x Genomics Inc share price expectations, FactSet research, analysts set an average price target of 20 in the next 12 months, up nearly 0.05% from the previous closing price of $19.99. Analysts anticipate 10x Genomics Inc stock to reach 22 by 2026, with the lowest price target being 13. In spite of this, 8 analysts ranked 10x Genomics Inc stock as Hold at the end of 2026. On September 03, 2024, Leerink Partners assigned a price target of “an Outperform” to the stock and initiated coverage with a $35.
